Hawkinsinuria

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:2118OMIM:140350E70.2
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Hawkinsinuria is an extremely rare inherited disorder of tyrosine metabolism caused by a defect in the enzyme 4-hydroxyphenylpyruvate dioxygenase (4-HPPD), encoded by the HPD gene. Unlike most other inborn errors of tyrosine catabolism, hawkinsinuria follows an autosomal dominant inheritance pattern. The condition is named after the Hawkins family, in whom it was first described. The enzymatic defect leads to the accumulation of an unusual amino acid metabolite called hawkinsin (2-L-cysteinyl-S-yl-1,4-dihydroxycyclohex-5-en-1-yl acetic acid) in the urine, along with other abnormal metabolites including 4-hydroxycyclohexylacetic acid. The disorder primarily affects the metabolic system, specifically the tyrosine degradation pathway in the liver. In infancy, affected individuals may present with failure to thrive, metabolic acidosis, and elevated blood tyrosine levels, particularly when exposed to a high-protein diet or standard infant formula. Symptoms in infancy can include poor weight gain, lethargy, and a characteristic body odor resembling a swimming pool (due to abnormal metabolites). Interestingly, many affected adults are clinically asymptomatic, with the biochemical abnormality (hawkinsinuria) persisting but without significant clinical consequences. Treatment during infancy primarily involves dietary management, specifically the restriction of phenylalanine and tyrosine intake. Breastfeeding has been noted to be protective, as breast milk has a relatively low protein content compared to standard infant formulas. With appropriate dietary management during the vulnerable infantile period, affected children typically improve and may become clinically well, though they continue to excrete hawkinsin in their urine. Supplementation with vitamin C (ascorbic acid) has also been reported to be beneficial, as it may help support residual enzyme activity. Long-term prognosis appears to be favorable, with most individuals leading normal lives after the critical infantile period.

Also known as:

Clinical phenotype terms— hover any for plain English:

4-Hydroxyphenylpyruvic aciduriaHP:00031614-hydroxyphenylacetic aciduriaHP:0003607Abnormal circulating tyrosine concentrationHP:0010917
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Infantile

Begins in infancy, roughly 1 month to 2 years old

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Hawkinsinuria.

View clinical trials →

No actively recruiting trials found for Hawkinsinuria at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Hawkinsinuria community →

No specialists are currently listed for Hawkinsinuria.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Hawkinsinuria.

Search all travel grants →NORD Financial Assistance ↗

Community

Open HawkinsinuriaForum →

No community posts yet. Be the first to share your experience with Hawkinsinuria.

Start the conversation →

Latest news about Hawkinsinuria

No recent news articles for Hawkinsinuria.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Hawkinsinuria

What is Hawkinsinuria?

Hawkinsinuria is an extremely rare inherited disorder of tyrosine metabolism caused by a defect in the enzyme 4-hydroxyphenylpyruvate dioxygenase (4-HPPD), encoded by the HPD gene. Unlike most other inborn errors of tyrosine catabolism, hawkinsinuria follows an autosomal dominant inheritance pattern. The condition is named after the Hawkins family, in whom it was first described. The enzymatic defect leads to the accumulation of an unusual amino acid metabolite called hawkinsin (2-L-cysteinyl-S-yl-1,4-dihydroxycyclohex-5-en-1-yl acetic acid) in the urine, along with other abnormal metabolites

How is Hawkinsinuria inherited?

Hawkinsinuria follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Hawkinsinuria typically begin?

Typical onset of Hawkinsinuria is infantile. Age of onset can vary across affected individuals.